Business Wire

Abionic Receives IVDR Certification for Its Predictive Ultra-Rapid Sepsis Test Allowing the Management of Antibiotic Administration

Share

Abionic SA, a developer of disruptive nanotechnology-based diagnostic solutions, has announced that its Pancreatic Stone Protein (PSP) test on the abioSCOPE® has been certified by BSI certification agency as complying with the European In-vitro Diagnostic Regulation (IVDR), EU 2017/746. This certification granted by notified bodies like BSI is required for in-vitro diagnostics to continue being sold in the European Union. The IVDR’s extensive requirements were adopted by the European Parliament in 2017 and must now be implemented by May 26, 2022.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220808005159/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

FIVE MINUTES TO SAVE LIVES - Immediate clinical decision-making at your fingertips (Photo: Business Wire)

IVDR becomes mandatory as of May 26, 2022. There are also transitional rules that will allow well-established instruments that have not been IVDR certified, but that entered the EU before, to still be sold until 2025. Depending on their shelf life, they may also be used after 2025. Abionic has been preparing for IVDR compliance since 2019, and chose BSI, a reputable notified body that was authorized to perform this certification process.

“As part of its ongoing commitment to meeting the highest standards to ensure patient safety and meet customer needs, Abionic is proud to have achieved the required IVDR certification for its class C product,” stated Dr. Iwan Märki, CTO of Abionic.

Improving the management of antibiotic administration

Antibiotics are medicines that are used to prevent and treat bacterial infections, which have revolutionized healthcare since the 1930s and have been paramount in saving millions of lives. However, a systematic overuse and misuse of antibiotics is leading to a concerning increase in the number of antibiotic resistant bacteria, which are becoming harder to treat and causing more severe and fatal infections. International and national healthcare organizations such as the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) have identified antibiotic resistance as one of the biggest threats to global health today. The over-prescription of antibiotics by healthcare workers is a key contributing factor leading to resistance, with a direct relationship between antibiotic consumption and the emergence and dissemination of resistant bacteria strains (Nature. 2013:495(7440):141). Studies have shown that antibiotic therapy is incorrectly prescribed in as many as 60% of patients receiving hospital care and is likely to be even higher outside this environment (Luyt et al., Critical Care, 2014). Aside from contributing to resistance, inappropriate antibiotic use may lead to increased mortality and severe disease, increased healthcare costs, increased lengths of stay in hospital and the need for more complex treatments leading to a higher risk for adverse effects and unwanted drug interactions.

Dr. Samir Vora, infectious disease physician, Geneva, Switzerland, commented: “The PSP assay has the potential to help the physician decide whether or not to start antibiotic therapy, and thus contribute to reducing the two major public health problems of sepsis and antimicrobial resistance.”

Two years after the commercial launch of its sepsis test, Abionic’s expansion is reaching a global scale. With over 50 markets already covered, Abionic’s next big step is the U.S. where sepsis represents the single largest cost to the healthcare system. Clinical trials to support FDA 510(k) submission are well underway. “As we gear up for FDA clearance, it’s very motivating to see how excited the U.S. ecosystem is about our novel approach to detecting sepsis and its potential impact on lifespan and healthcare costs,” said Nelson Dumas, Director of the U.S. Subsidiary of Abionic.

About Abionic

Founded in 2010, Abionic is a Swiss Medtech company commercializing a revolutionary nanofluidic technology, providing healthcare professionals with a fast, simple and universal diagnostic tool. Abionic’s cutting-edge nanotechnology enhances the efficiency and versatility of standard ELISA tests to deliver optimal point of care (POC) treatment options by reducing current biological measuring techniques from the macroscale down to the nanoscale in a multi-analyte environment.

Abionic’s In Vitro Diagnostic (IVD) platform provides lab-quality ultra-fast results from a single drop of patient sample (saliva, blood, urine, etc.) at the POC enabling personalized diagnostics and opening the window of opportunity for immediate treatment. The company is mainly active in acute care and in primary care (COVID-19, allergy, iron deficiency) businesses.

For further information about Abionic, please visit https://www.abionic.com/.
For further information about IVDR, please visit: EUR-Lex

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Dr. Nicolas Durand
CEO
Abionic SA
+41 (0)21 353 33 80
info@abionic.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ALL4PACK Emballage Paris – 21 to 24 November 2022: the leading international trade fair for all sustainable packaging and intralogistics solutions26.9.2022 10:00:00 CEST | Press release

The benchmark event at the end of the year (21-24 November 2022 - Paris Nord Villepinte, France), ALL4PACK Emballage Paris is the leading international trade fair for all sustainable packaging and intralogistics solutions, covering the whole production line, including machines. ALL4PACK is a source of inspiration, offering support to all industry stakeholders who are faced with ongoing and future challenges. Against this backdrop, the fair stands out by decoding market developments and regulations, and by showcasing the latest innovations. A new approach approved by exhibitors ALL4PACK Emballage Paris offers a complete range of packaging and machinery solutions for all types of industry. To date, 1,300 exhibitors are expected, of which about 50% are international exhibiters. In fact, 96% of the exhibition space has already been booked. Various leading companies such as ATLANTA STRETCH, AUER, BFR SYSTEMS, DOMINO, FILPACK, FRANPACK, FROMM, G.MONDINI, GETRA, GOGLIO, ISHIDA, KRONES, MARCHE

Adams Street Hires James Charalambides and Launches European Private Credit Strategy26.9.2022 10:00:00 CEST | Press release

Adams Street Partners, LLC, a private markets investment firm with $50 billion in assets under management, announced the launch of its Private Credit platform in Europe with the appointment of James Charalambides as Partner & Head of the European Private Credit team. Mr. Charalambides will be responsible for leading and managing the firm’s private credit-related efforts in Europe and supporting all aspects of the decision-making process – including sourcing, structuring, reviewing, and negotiating deal opportunities in this space. Mr. Charalambides will report to Bill Sacher, Partner & Head of Private Credit at Adams Street. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220926005177/en/ Adams Street Partners has announced the launch of its Private Credit platform in Europe with the appointment of James Charalambides as Partner & Head of the European Private Credit team. (Photo: Business Wire) Since launching its inaugural p

Guillaume Jesel Promoted to President, Global Brands, TOM FORD BEAUTY, BALMAIN BEAUTY and Luxury Business Development26.9.2022 09:00:00 CEST | Press release

Today, The Estée Lauder Companies (NYSE: EL) (“ELC”) announced that Guillaume Jesel has been promoted to President, Global Brands, TOM FORD BEAUTY, BALMAIN BEAUTY and Luxury Business Development, effective immediately. Guillaume will report to Jane Hertzmark Hudis, Executive Group President and also to Tracey T. Travis, Executive Vice President and Chief Financial Officer in her role of overseeing the company’s mergers and acquisitions strategy, for Guillaume’s Luxury Business Development responsibilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220926005235/en/ Guillaume Jesel has been promoted to President, Global Brands, TOM FORD BEAUTY, BALMAIN BEAUTY and Luxury Business Development (Photo: Business Wire) In this new position, Guillaume will continue to oversee TOM FORD BEAUTY and also be responsible for the overall strategic direction, global development, management and growth of BALMAIN BEAUTY. Guillaume will wo

Alipay+ Partners with Leading Asian E-Wallets to Promote Cashless Travel in South Korea26.9.2022 08:45:00 CEST | Press release

Leading mobile payment providers across Asia announced today an integration of Alipay+ cross-border digital payment solutions in South Korea in an effort to jointly promote cashless travel in the country. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220925005072/en/ Users of leading Asian e-wallets including AlipayHK, GCash (the Philippines), Touch ‘n Go (Malaysia), and TrueMoney (Thailand) are able to pay at over 120,000 merchants using their local mobile payment apps when traveling in South Korea. (Photo: Business Wire) Users of e-wallets including AlipayHK, GCash (the Philippines), Touch ‘n Go eWallet (Malaysia), and TrueMoney (Thailand) are able to pay at over 120,000 merchants using their local mobile payment apps when traveling in South Korea. The collaboration marks the first time for leading mobile payment providers from Southeast Asia and Hong Kong to extend the availability of their services in South Korea throug

The Estée Lauder Companies and BALMAIN are Partnering to Launch BALMAIN BEAUTY26.9.2022 08:00:00 CEST | Press release

The Estée Lauder Companies Inc. (NYSE: EL) (“ELC”) and BALMAIN have entered into a license agreement to collaboratively develop, produce, and distribute an innovative line of beauty products that will speak to luxury consumers around the world: BALMAIN BEAUTY. The collaboration is expected to launch in fall 2024, with the goal to transform the luxury and couture beauty world through exceptional design, singular craftsmanship, and an unyielding commitment to innovation. In 1945, when founder Pierre Balmain boldly introduced his audacious, fresh, and feminine “New French Style,” Balmain helped post-war Paris begin to regain its title as the fashion world’s capital. Today’s BALMAIN, under the visionary leadership of Creative Director Olivier Rousteing since 2011, builds upon Pierre Balmain’s legacy, with the house’s rich archives providing key inspirations and the legendary savoir-faire of Balmain’s atelier ensuring the success of Rousteing’s distinctive “Renewed French Style.” While reve

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom